Acid Ceramidase Inhibitors: A De Novo Drug Target and a New Class of Drug for Glioblastoma Glioblastoma remains the most common malignant cancer of the central nervous system with an overall survival <1.5 years. Therapeutically resistant glioblastoma or glioblastoma stem-like... Read More